Cystic fibrosis organizations
Links to helpful information for you and your patients
Genentech does not recommend and does not endorse the content on any third-party websites. Genentech is not responsible for the content of linked third-party sites and does not make any representations regarding their content or accuracy. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
Foundation: This Foundation is committed to raising awareness
about CF and funding CF research, and it provides numerous ways to
get involved in the fight against CF.
Foundation: The Cystic Fibrosis Foundation is the leading
organization in the United States devoted to cystic fibrosis, and
its website provides a wealth of information. The mission of this
nonprofit, donor-supported organization is to assure the development
of the means to cure and control cystic fibrosis and to improve the
quality of life for those with the disease.
Cystic Fibrosis Research,
Inc.: CFRI is a nonprofit organization founded in 1975. CFRI’s
mission is to fund research, provide educational and personal
support, and spread awareness of cystic fibrosis (CF), a
life-threatening genetic disease.
Community: CysticLife.org is a social network just for the
cystic fibrosis community. This positive, uplifting website is the
central location for the CF community to share tips, questions,
ideas, experiences, and encouragement.
- Mayo Clinic: The CF section of the Mayo Clinic website can provide your patients with a full overview of the disease, along with information about symptoms, causes, risk factors, and what to expect during the treatment process.
Important Safety Information & Indication
Pulmozyme (dornase alfa) is indicated for daily administration in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.
In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
Important Safety Information
Pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any component of the product.
The most common adverse reactions associated with the use of Pulmozyme include: voice alteration, pharyngitis, rash, laryngitis, chest pain, conjunctivitis, rhinitis, decrease in FVC of ≥ 10%, fever, dyspepsia, and dyspnea. There have been no reports of anaphylaxis attributed to the administration of Pulmozyme. Mild to moderate urticaria and mild skin rash have been observed and have been transient.
The safety and effectiveness of Pulmozyme have been established in pediatric patients 5 years of age and older. The safety of Pulmozyme, 2.5 mg by inhalation, was studied with 2 weeks of daily administration in 65 patients with cystic fibrosis aged 3 months to < 5 years. While clinical trial data are limited in pediatric patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in pulmonary function or who may be at risk of respiratory tract infection.
The safety of Pulmozyme, 2.5 mg by inhalation, was studied with 2 weeks of daily administration in 98 pediatric patients with cystic fibrosis 3 months to 10 years of age (65 aged 3 months to < 5 years, 33 aged 5 to ≤ 10 years). The PARI BABY™ reusable nebulizer (which uses a facemask instead of a mouthpiece) was utilized in patients unable to demonstrate the ability to inhale or exhale orally throughout the entire treatment period (54/65, 83% of the younger; and 2/33, 6% of the older patients). Overall, the nature of adverse reactions was similar to that seen in the placebo-controlled trials in older patients. The number of patients reporting cough was higher in the younger age group as compared to the older age group (29/65, 45%; compared to 10/33, 30%) as was the number reporting moderate to severe cough (24/65, 37%; compared to 6/33, 18%). The number of patients reporting rhinitis was higher in the younger age group as compared to the older age group (23/65, 35%; compared to 9/33, 27%) as was the number reporting rash (4/65, 6% as compared to 0/33, 0%).